DEFA14A: Enhabit Defends Strategy Against AREX Capital, Urges Stockholders to Support Director Nominees

Enhabit, Inc. addresses misstatements by AREX Capital Management, defending its progress in stabilizing the business and urging stockholders to vote for its director nominees.

Summary

• Enhabit, Inc. has sent a letter to stockholders addressing misstatements made by AREX Capital Management, LP, regarding the company's performance and strategic direction.
• The letter defends Enhabit's progress in stabilizing the business after its separation from Encompass Health Corporation, citing challenges and improvements in Medicare Advantage contracts and hospice admissions.
• Enhabit's Board of Directors recommends stockholders vote for its director nominees at the upcoming 2024 Annual Meeting of Stockholders on July 25, 2024, arguing that AREX's proposed changes threaten the company's recent stabilization.
• The company addresses AREX's critiques regarding Medicare Fee-for-Service market share, hospice business performance, and overhead costs, providing data and explanations to counter AREX's claims.
• Enhabit emphasizes that it has outperformed its standalone cost plan for 2023 by 15% and that its home office G&A as a percentage of revenue is ahead of its closest public peer, Amedisys.
• The company defends its strategic review process, stating that it was comprehensive and exhaustive, and accuses AREX of pivoting its approach after the termination of the review.
• Enhabit urges stockholders to protect the value of their investment by voting for Enhabit's superior Board via the YELLOW proxy card.

Sentiment

Score: 7

Explanation: The document presents a defensive but optimistic tone, highlighting improvements and defending against criticisms. While acknowledging past challenges, it emphasizes stabilization and future growth potential.

Positives

• Enhabit has stabilized its business and is positioned for profitable growth.
• The company has negotiated 64 new Medicare Advantage contracts since the spin-off, improving rates.
• Enhabit's hospice business has shown growth in revenue and admissions, outperforming Amedisys in these metrics.
• The company has outperformed its standalone cost plan for 2023 by 15%.
• Enhabit's home office G&A as a percentage of revenue is ahead of its closest public peer, Amedisys.

Negatives

• Enhabit's financial results and stock performance have not satisfied stockholder expectations.
• The company faced substantial industry and company-specific headwinds after its separation from Encompass Health Corporation.
• AREX Capital Management is running a proxy contest to replace seven of the eight independent directors, which Enhabit believes threatens the recent stabilization of the business.

Risks

• The proxy contest initiated by AREX Capital Management could disrupt Enhabit's strategic plans and management.
• Failure to continue executing on initiatives and improving performance could negatively impact the company's value creation.
• Changes in reimbursement rates, general economic conditions, and the episodic versus non-episodic mix of payors could affect Enhabit's financial results.
• The company's ability to attract and retain key management personnel and healthcare professionals is crucial for its success.
• Potential disruptions or breaches of information systems could negatively impact operations.

Future Outlook

Enhabit expects future Medicare Advantage contracts will continue to enhance the profitability of the business and that it is positioned for success going forward.

Management Comments

• We understand that neither our financial results nor our stock performance has satisfied your expectations.
• Our performance over the last two quarters indicates that the business has stabilized and is positioned for profitable growth moving forward.
• We have the right strategy and right set of directors to oversee our strategy and the management of Enhabit.

Industry Context

The document highlights the shift from traditional Medicare to Medicare Advantage plans and how Enhabit is adapting to this trend. It also compares Enhabit's performance to that of Amedisys, a public peer, in terms of hospice revenue and admissions growth.

Comparison to Industry Standards

• Enhabit's Home Health Medicare revenue mix is 61%, which is in-line with Amedisys, its only public peer with a similar business and payor mix.
• Enhabit's hospice revenue grew by 2.9% from Q2 2022 to Q1 2024, while Amedisys revenue grew by 1.3% during the same period.
• Enhabit's hospice admissions grew by 6.9% from Q2 2022 to Q1 2024, while Amedisys admissions declined by 5.3% during the same period.
• Enhabit's home office G&A as a percentage of revenue is at approximately 10%, which is ahead of Amedisys, at approximately 11%.

Stakeholder Impact

• The outcome of the proxy contest will impact the composition of the Board of Directors and the strategic direction of the company, affecting shareholders.
• The company's performance and strategic decisions will impact employees, patients, and other stakeholders.

Next Steps

• Stockholders are urged to vote for Enhabit's director nominees via the YELLOW proxy card.
• The company will continue to execute on its initiatives and improve performance.

Key Dates

Keywords

Enhabit, AREX Capital Management, proxy contest, home health, hospice, Medicare Advantage, Board of Directors, stockholders, strategic review, Encompass Health